These are the clinical trials that led to the FDA’s approval of aducanumab and lecanemab for early AD, plus, the concerns that loom.
All articles by Tori Rodriguez, MA, LPC, AHC
Mehdi Jorfi, PhD, discusses the opportunities to optimize the development and application of neurotechnologies for AD.
Timothy S. Chang, MD, PhD and Lisa L. Barnes, PhD, discuss health disparities in ADRD and how to improve clinical outcomes for patients from underrepresented groups.
Aduhelm, a monoclonal antibody that targets amyloid-beta, is covered under Medicare for beneficiaries enrolled in clinical trials.
David Howell, PhD; and Heather Sesma, PhD; provide insight into the specific sequelae of concussion in youth and risk for subsequent mental health issues.
In this review, study authors discuss and summarize the current evidence for the evaluation and management of the most prevalent and well-described conditions in SCI, including impact of SCI on sleep and daytime function.
The clinical approach to management of Cushing disease is often complex and education on a clear approach is paramount.
Studies show increased rate of all types of dementia in patients with AF, with new data finding treatment of AF lowers risk for cognitive dysfunction.
Researchers found data that showed, after consultation with an expert, optimal prevention of migraine headaches for patients who present in the emergency department includes both antiseizure medications, specifically, divalproex sodium, sodium valproate, or topiramate, and β-blockers, namely, metoprolol, propranolol, and timolol. In addition, triptans are suggested, as well as antidepressants, amitriptyline, and venlafaxine.